Core Viewpoint - The U.S.-China trade friction has extended its impact to the in vitro diagnostics (IVD) industry, which is a crucial part of China's modern healthcare system, heavily reliant on global supply chains and facing significant import-export imbalances [1][2]. Industry Overview - The IVD industry in China is the only medical device sector where imports exceed exports, with imports of IVD reagents and instruments projected to reach 41.679 billion yuan and 15.408 billion yuan respectively in 2024, accounting for 17% and 6.28% of total medical device imports [1]. - The domestic IVD market is dominated by biochemical, immunological, and molecular diagnostics, which together account for over 70% of the market share [3]. Domestic Development and Market Dynamics - The domestic IVD industry has made significant strides in localization, with 60%-70% of products in key areas like biochemical diagnostics and PCR testing now being domestically produced [3]. - The immunodiagnostics segment is the largest in the IVD market, valued at approximately 50.3 billion yuan in 2023, representing 42.45% of the market share [4]. - Despite the growth in domestic production, foreign companies still dominate the immunodiagnostics market, with Roche holding a 25.4% market share [4][5]. Technological Advancements - The molecular diagnostics sector is experiencing rapid growth, particularly following the COVID-19 pandemic, which has increased public awareness and demand for such technologies [7]. - Domestic companies have achieved significant advancements in PCR technology, with local instruments demonstrating competitive efficiency compared to foreign counterparts [7][8]. Challenges and Opportunities - The IVD industry faces challenges in achieving complete self-sufficiency in core raw materials and processes, with many critical components still reliant on imports [9][10]. - The current tariff policies have increased the cost pressure on imports, creating a window of opportunity for domestic raw material suppliers to gain market share [12]. - The domestic market is characterized by a tendency towards product homogeneity, which poses a challenge for companies to achieve differentiation and quality control [13].